Ernexa Therapeutics Inc (ERNA)

Currency in USD
7.390
-0.500(-6.34%)
Closed·
7.600+0.210(+2.84%)
·
ERNA is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
7.3908.050
52 wk Range
1.27075.000
Key Statistics
Prev. Close
7.89
Open
7.93
Day's Range
7.39-8.05
52 wk Range
1.27-75
Volume
39.92K
Average Volume (3m)
1.6M
1-Year Change
-89.5732%
Book Value / Share
5.88
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ERNA Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
30.000
Upside
+305.95%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Ernexa Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 30.000
(+305.95% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Earnings

Latest Release
20-05-2026
EPS / Forecast
-6.95 / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

ERNA Income Statement

Compare ERNA to Peers and Sector

Metrics to compare
ERNA
Peers
Sector
Relationship
P/E Ratio
−0.8x−4.5x−0.5x
PEG Ratio
−0.010.000.00
Price/Book
1.3x1.7x2.6x
Price / LTM Sales
-7.0x3.0x
Upside (Analyst Target)
306.0%106.6%58.6%
Fair Value Upside
Unlock14.7%10.2%Unlock

Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company’s lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
7.44K0.64%58.68K
Other Institutional Investors
142.82K12.25%1.13M
Public Companies & Retail Investors
1.02M87.12%8.02M
Total
1.17M100.00%9.2M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Vanguard Index Funds - Vanguard Extended Market ETF0.49%5,68345
Vanguard Fiduciary Trust Co. Institutional Extended Market Index Trust Fund0.09%1,0178

FAQ

What Is the Ernexa Therapeutics (ERNA) Share Price Today?

The Ernexa Therapeutics share price today is 7.390.

What is the current Ernexa Therapeutics (ERNA) share price and day range?

As of 09-06-2026, the Ernexa Therapeutics share price is 7.390, with a previous close of 7.890. The share price has ranged from 7.390 to 8.050 today, while the 52-week range spans from 1.270 to 75.000.

What Is the Ernexa Therapeutics Market Cap?

As of today, Ernexa Therapeutics market cap is 8.720M.

What Is the Ernexa Therapeutics (ERNA) Share Price Target?

The average 12-month share price target for Ernexa Therapeutics is 30.000, with a high estimate of 30 and a low estimate of 30. 1 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +305.95% Upside potential.

What Is Ernexa Therapeutics's Earnings Per Share (TTM)?

The Ernexa Therapeutics EPS (TTM) is -27.494.

When Is the Next Ernexa Therapeutics Earnings Date?

Ernexa Therapeutics will release its next earnings report on 17-08-2026.

From a Technical Analysis Perspective, Is ERNA a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

What Stock Exchange Does Ernexa Therapeutics Trade On?

Ernexa Therapeutics is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Ernexa Therapeutics?

The stock symbol for Ernexa Therapeutics is "ERNA."

How Many Times Has Ernexa Therapeutics Stock Split?

Ernexa Therapeutics has split 6 times.

How Many Employees Does Ernexa Therapeutics Have?

Ernexa Therapeutics has 6 employees.

What Is the ERNA Premarket Price?

ERNA's last pre-market stock price is 8.050. The pre-market share volume is 820.000, and the stock has changed by 0.160, or 2.030%.

What Is the ERNA After Hours Price?

ERNA's last after hours stock price is 7.600, the stock has changed by 0.210, or 2.840%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.